Technical Advantage
Enzyme inhibition technology
Specific protease inhibitors protect peptide proteins from degradation by gastrointestinal enzymes and improve drug stability.
Penetration promotion
Innovative intestinal penetration enhancers reversibly open tight junctions in epithelial cells, promoting drug absorption.
nanocarrier
Biodegradable nanocarriers encapsulate drugs to achieve targeted release and transmembrane transport in the intestine.
High bioavailability
The combination of multiple strategies enables oral bioavailability to reach over 5% of injection administration, meeting clinical needs.
Good safety
All excipients used are pharmaceutical excipients recorded in pharmacopoeia, with good safety and no obvious gastrointestinal irritation.
widely applicable
The platform technology is applicable to various peptide and protein drugs, and can quickly develop different varieties of oral preparations.
Technical Principles
Oral administration of peptide protein drugs faces two major challenges: firstly, proteases in the gastrointestinal tract degrade the drugs into inactive fragments; Secondly, polypeptide proteins have a large molecular weight and strong hydrophilicity, making it difficult to penetrate the intestinal epithelial cell membrane. UKOral technology solves these problems through a triple strategy system of "protection promotion delivery".
Firstly, protect the integrity of drugs in the gastrointestinal tract through enzyme inhibitors and pH regulation; Secondly, using penetration enhancers to enhance intestinal epithelial permeability; Finally, targeted intestinal release and transmembrane transport of drugs are achieved through nanocarriers. Triple strategy synergy achieves efficient oral absorption.
Application Achievements
UKOral technology has made breakthrough progress in oral GLP-1 receptor agonists and oral insulin. The oral GLP-1 formulation achieved a bioavailability of 5% in animal experiments, and its hypoglycemic effect was comparable to subcutaneous injection.